| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4780505
Max Phase: Preclinical
Molecular Formula: C29H32BrN3O4
Molecular Weight: 566.50
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COC(=O)[C@@H]1[C@H]2C[C@@H](OCc3ccc(Br)cc3)c3[nH]c4ccccc4c3CCN(C#N)C[C@@H]2CC[C@@H]1O
Standard InChI: InChI=1S/C29H32BrN3O4/c1-36-29(35)27-23-14-26(37-16-18-6-9-20(30)10-7-18)28-22(21-4-2-3-5-24(21)32-28)12-13-33(17-31)15-19(23)8-11-25(27)34/h2-7,9-10,19,23,25-27,32,34H,8,11-16H2,1H3/t19-,23-,25-,26+,27+/m0/s1
Standard InChI Key: PORCWYGYBFXAHK-JWRODKNGSA-N
Associated Targets(Human)
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CCR3 Tchem C-C chemokine receptor type 3 (1666 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CCR8 Tchem C-C chemokine receptor type 8 (339 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CX3CR1 Tchem C-X3-C chemokine receptor 1 (1686 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CXCR4 Tclin C-X-C chemokine receptor type 4 (3338 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
FSHR Tclin Follicle stimulating hormone receptor (234 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
OXTR Tclin Oxytocin receptor (1962 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PRLHR Tchem Prolactin-releasing peptide receptor (450 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 566.50 | Molecular Weight (Monoisotopic): 565.1576 | AlogP: 5.09 | #Rotatable Bonds: 4 |
| Polar Surface Area: 98.58 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
| #RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.70 | CX LogD: 4.70 |
| Aromatic Rings: 3 | Heavy Atoms: 37 | QED Weighted: 0.34 | Np Likeness Score: 0.58 |
References
| 1. Paciaroni NG,Norwood VM,Ratnayake R,Luesch H,Huigens RW. (2020) Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets., 28 (14): [PMID:32616180] [10.1016/j.bmc.2020.115546] |
Source
Source(1):